Cassava Sciences (NASDAQ:SAVA) has tapped Freda Nassif as chief commercial officer, effective Nov. 18, 2024. Ms. Nassif is an ...

Cassava Sciences, Inc. (NASDAQ: SAVA), a clinical-stage biotechnology company focused on developing a novel treatment for ...

Bearish flow noted in Cassava Sciences (SAVA) with 3,180 puts trading, or 1.8x expected. Most active are 11/22 weekly 13 puts and 11/22 weekly 25 puts, with total volume in those strikes near 1,000 ...

On Friday, Cassava Sciences Inc (SAVA) stock saw a modest uptick, ending the day at $26.91 which represents a slight increase of $0.77 or 2.95% from the prior close of $26.14. The stock opened at $26.

Here is how Cassava Sciences, Inc. (SAVA) and biote Corp. (BTMD) have performed compared to their sector so far this year.

SEC adopts EDGAR Next - As outlined in this October 22 Cooley alert, the Securities and Exchange Commission (SEC) adopted final ...

STAT+ subscribers can sign up here to get it delivered to their inbox. As we count down toward the December readout of ...

Cassava Sciences, Inc. (SAVA) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting ...

BioSpace takes a look at the headlines across a heavy earnings week for biotechs, checking in on Allogene, Rapport and more.

Detailed price information for Cassava Sciences Inc (SAVA-Q) from The Globe and Mail including charting and trades.

Panax ginseng shows highest effectiveness in treating Alzheimer's. Learn more about AVXL's blarcamesine and SAVA's simufilam ...

Cassava Sciences, Inc. (NASDAQ:SAVA) Q3 2024 Earnings Call Transcript November 7, 2024 Cassava Sciences, Inc. beats earnings ...